WHO Sounds Alert Over Acute Lack of Obesity Medications

Fewer than 10% of patients who could benefit from obesity jabs such as Wegovy can access them, caution the global health agency as it issues its first guidance on the drugs.

With in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for more widespread and fairer availability to GLP-1 medication.

Based on estimates, over two billion are projected to be obese by 2030 without intervention.

"The new guidance acknowledges that obesity is a chronic disease that can be managed with comprehensive and continuous treatment," stated the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and logistical bottlenecks are major barriers to widespread availability to the injections that can assist patients in reducing considerable weight, explains the organization.

Skinny Jab Supply Crisis

Even in the present most optimistic outlook, the supply of such drugs might only reach around 100 million people – under 10% of the global need, according to the health organization.

The recommendation urges countries and companies to widen access, via strategies such as voluntary licensing.

The intellectual property rights on the active ingredient – the main ingredient of a leading brand – is set to lapse in a number of countries in 2026.

The Way Weight-Loss Drugs Operate

The injections imitate a natural hormone to delay gastric emptying, reduce hunger and enhance satiety so individuals eat less.

Patients typically see weight reduction within a few weeks of beginning the weekly injections.

Studies suggests users may regain a significant portion a year later of discontinuing the drug, as their usual appetite resume.

To be overweight or obese increases your chance for developing health problems, like diabetes, cardiovascular issues, brain attack, and certain cancers.

Excess weight affects people in every country and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.